Figma

Preliminary trading in shares of Figma, a developer of user interface design service, which Adobe wanted to buy for $20 billion, has started in the trading system for Freedom clients. The securities are available under the ticker <a href="https://app.tradernet.global/to/quote/FIG.US">FIG.US</a>. They will appear on the New York Stock Exchange later Thursday.

Figma IPO: shares of Adobe's competitor started trading

Shoulder Innovations, Inc.

Shares of Shoulder Innovations, a medical company that develops implants for shoulder surgeries, became available July 31 on the Freedom client trading system. The securities are listed under the ticker <a href="https://tap.freedom24.com/to/quote/SI.US?utm_source=stocks&amp;utm_medium=SI.US&amp;utm_campaign=pfu8656964">SI</a>. They will appear on the New York Stock Exchange in a few hours.&nbsp;

Shoulder Innovations IPO: shares of medtech with AI solutions for surgery become available


Ambiq Micro, Inc.

The company raised $96 million by selling shares near the top of its stated range

Ambiq Micro IPO: Shares of AI chip developer become available


DXC Technology Company

Analysts recommend buying the stock but keeping the position to 2% of portfolio or less

Freedom Broker sees 23% short-term upside in DXC amid deleveraging, cheap multiples


Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Viking Therapeutics, a clinical-stage biotech developing, among other things, an oral weight-loss drug, has reported a net loss a third bigger than the market expected and is set to further increase R&amp;D spending. That said, the company is still considered a leading small-/mid-sized player in the weight-loss drug market and could pose a threat to Novo Nordisk and Eli Lilly with their injected therapies, Wall Street believes.&nbsp;

Oral weight-loss drugmaker Viking reports widening loss in 2Q, guides for higher R&D

McGraw Hill, Inc.

The company has placed the shares below the stated range

McGraw Hill IPO: shares of education legend with a focus on EdTech become available


Accelerant Holdings

Preliminary trading in shares of insurance platform Accelerant Holdings, in which co-owner of Chelsea soccer club Todd Bowley invested, started on July 24 in the system for Freedom clients. The securities are available by ticker symbol <a href="https://tradernet.global/what-to-buy/stocks/ARX.US">ARX</a>. They will appear on the New York Stock Exchange later Thursday.

Accelerant IPO: trading in shares of the platform for insurers and investors has started

NIQ Global Intelligence

Preliminary trading in shares of NIQ Global Intelligence has begun on the Freedom client trading system. The securities of the global market leader in consumer analytics, known as NielsenIQ, are available under the ticker symbol <a href="https://tradernet.global/what-to-buy/stocks/NIQ.US">NIQ</a>. They will appear on the New York Stock Exchange later Wednesday.&nbsp;

NIQ IPO: shares of the analytics provider for Coca-Cola and Amazon begin trading


Carlsmed

Shares of Carlsmed, a provider of specialized artificial intelligence-based equipment and software for personalized spine surgeries, have become available to investors on the Freedom customer trading system. The securities are listed under the ticker symbol CARL. They will appear on the Nasdaq exchange in a few hours;

Carlsmed IPO: Shares in Carlsmed, a pioneer in AI spine surgery, become available


Incyte Corporation

Jefferies Financial Group Inc.

ServiceTitan, Inc.

The companies operate in health care, tech and finance

Three sectors, three stocks: Freedom gives mid-cap ideas for next 12 months

Papa John's International, Inc.

Freedom Broker has put out a short-term trade idea to buy shares of pizza chain Papa John's. In the next two months, the stock has upside of almost 16%, Freedom Broker estimates. The company has had a rough last few years, but new leadership is implementing a new course, betting on tech innovation and expanding internationally.

Freedom Broker issues short-term 'buy' for Papa John's as turnaround continues

Candel Therapeutics, Inc.

Freedom Broker has initiated on Candel Therapeutics, which&nbsp;develops immunotherapies for cancer patients, and estimates the stock has upside of more than 100%. The company has low debt and a large cash pile to finance operations, Freedom Broker points out.

Freedom Holding